Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.69 |
| ▸ | MMP2 | P08253 | 10/20 | 0.68 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.61 |
| ▸ | MMP7 | P09237 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1523717 | 1.00 | MMP9 (0.69) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| Chloromethane SCHEMBL7649372 | 0.92 | MMP2 (0.75) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| SCHEMBL697477 | 0.92 | MMP2 (0.79) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| SCHEMBL1203540 | 0.92 | MMP2 (0.79) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| SCHEMBL697476 | 0.92 | MMP2 (0.79) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| SCHEMBL3856155 | 0.91 | MMP2 (0.73) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| Hydrochloric Acid SCHEMBL3839410 | 0.91 | MMP2 (0.77) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| Hydrochloric Acid SCHEMBL11133046 | 0.91 | MMP2 (0.77) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| SCHEMBL433897 | 0.90 | MMP2 (0.71) | MMP9MMP2ADAMTS4TDP1ADAMTS5 | |
| SCHEMBL561565 | 0.90 | MMP2 (0.71) | MMP9MMP2ADAMTS4TDP1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 980 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458582-B2 | Stabilized hyaluronic acid | CROMA-PHARMA GMBH (AT) | 2025-11-04 | — | — | US | claimed |
| WO-2023089533-A1 | TANDEM TRIPLE QUADRUPOLE MASS SPECTROMETER-BASED SCREENING AND CONFIRMATION METHOD FOR ANALYZING PROTEIN AND ITS VARIANTS | NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PRIVATE LIMITED (IN) | 2023-05-25 | — | — | WO | claimed |
| US-20210332108-A1 | METHOD FOR PREPARING PEPTIDE FRAGMENTS, METHOD FOR PREPARING PROTEASE TO BE USED THEREIN, AND KIT FOR PREPARING PEPTIDE FRAGMENTS | SHIMADZU CORPORATION (JP) | 2021-10-28 | — | — | US | claimed |
| EP-3495480-A1 | METHOD FOR PREPARING PEPTIDE FRAGMENTS, METHOD FOR PREPARING PROTEASE TO BE USED THEREIN, AND KIT FOR PREPARING PEPTIDE FRAGMENTS | Shimadzu Corporation (JP) | 2019-06-12 | — | — | EP | claimed |
| EP-2819665-B1 | PROTEASE INHIBITORS FOR TREATING TRICHOMONAS GALLINAE INFECTIONS | VETERINÄRMEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2017-02-22 | — | — | EP | claimed |
| EP-2633855-A1 | Protease inhibitors for treating Trichomonas gallinae infections | Veterinärmedizinische Universität Wien (AT) | 2013-09-04 | — | — | EP | claimed |
| US-20110263521-A1 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-10-27 | — | — | US | claimed |
| US-20100323985-A1 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-12-23 | — | — | US | claimed |
| US-20100298249-A1 | PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-25 | — | — | US | claimed |
| US-20100003748-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR STABILIZATION OF A CELL AND/OR MACROMOLECULE | SIERRA MOLECULAR CORPORATION | 2010-01-07 | — | — | US | claimed |
| EP-1549758-A2 | FELINE PANCREATIC LIPASE COMPOSITION AND METHOD OF PREPARING AND USING SUCH COMPOSITION | Texas A & M University System (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2003093232-A2 | FELINE PANCREATIC LIPASE COMPOSITION AND METHOD OF PREPARING AND USING SUCH COMPOSITION | TEXAS A & M UNIVERSITY SYSTEM (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030207333-A1 | Feline pancreatic lipase composition and method of preparing and using such composition | TEXAS A&M UNIVERSITY SYSTEM, THE | 2003-11-06 | — | — | US | claimed |
| EP-1238099-A2 | AUTOMATED LYSOPHOSPHOLIPID ASSAY AND METHODS OF DETECTING CANCER | ABBOTT LABORATORIES (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001032916-A2 | AUTOMATED LYSOPHOSPHOLIPID ASSAY AND METHODS OF DETECTING CANCER | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | claimed |
| US-6171786-B1 | CONTACTING CELL WITH PHOSPHOINOSITOL-DEPENDENT PHOSPHOLIPASE C INHIBITOR ALONG WITH CYTOTOXIC DRUG | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS | 2001-01-09 | — | — | US | claimed |
| US-5695928-A | CONCURRENT EXTRACTION, COMPLEXING | NOVARTIS CORPORATION | 1997-12-09 | — | — | US | claimed |
| US-5518912-A | A PURE ENZYME ENDOGENOUS TO BIOLOGICAL CELLS OF THE SKIN OF XENOPUS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1996-05-21 | — | — | US | claimed |
| EP-0230670-B1 | NOVEL HOST E. COLI AND USE THEREOF | SUNTORY LIMITED (JP) | 1991-07-03 | — | — | EP | claimed |
| EP-0230670-A2 | Novel host E. coli and use thereof | SUNTORY LIMITED (JP) | 1987-08-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458582-B2 | Stabilized hyaluronic acid | CD44, HSPH1, ACR | MMP9 133/4885MMP2 106/4885ADAMTS4 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.